Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
NCX 470 NDA submitted in the U.S. by Kowa

July 1, 2026

What is the news ?

Nicox announces that its partner Kowa has submitted an NDA for NCX 470 to the U.S. FDA for the treatment of open-angle glaucoma and ocular hypertension, triggering a €3 million milestone payment to Nicox.

What does it mean ?

The filing marks a major step toward potential U.S. commercialization of NCX 470 and could provide Nicox with future milestone payments, royalties, and a new recurring revenue stream.

What are the next steps ?

The FDA is expected to review the application over a standard review period of 12 months, with a potential approval in mid-2027 and a U.S. launch before the end of 2027 if approved.
View Press Release Corporate presentation Contact us
Previous
Next